Company intelligence / Profile preview

Colospan

Kfar Saba, Sharon Area / Central District, Israelcolospan.com ↗

Ownership: Private
Development stage: Commercial

Overview

The CG‑100 intraluminal bypass device has completed a prospective multi-center trial with positive safety and feasibility results. It received CE marking in the EU (2014) and has completed verification/validation including animal studies. A pivotal IDE-approved randomized trial for rectal cancer patients is enrolling at multiple sites internationally to support US regulatory approval.

Therapeutic areas: GastroenterologyOncology
Modalities: Devicespecifically intraluminal bypass device
Industry: Surgical Medical Devices

Drug pipeline

1 asset

CG-100

Commercial

Indications: Colorectal surgery complications, Anastomotic leaks

Partnerships

European Union EIC Accelerator program funding partner

Beyond the preview

Go deeper on Colospan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Colospan.

Explore the full profile